

Registration number: 674647

Nextlab Pharma Limited

Abridged Financial Statements and Directors' Report

for the year ended 30th June 2025

(A Dormant Company)

Contents

Directors and other information	1
Directors' report	2
Statement of directors' responsibilities	3
Balance sheet	4
Notes to the accounts	5–6

Nextlab Pharma Limited

Directors and other information

Director(s)

Gabriel Imboden

Secretary

Corporate Compliance Services Limited

Company Registered Number

674647

Registered Office

3 Cavendish Row

Dublin 1

D01 A2T5

Nextlab Pharma Limited

Directors' Report for the year ended 30th June 2025

The directors present their report and the financial statements of the company for the year ended 30th June 2025.

Principal Activity and Business Review

The company did not trade during the year and has been dormant since incorporation. The directors do not anticipate any change in this activity in the foreseeable future.

Results

The company had no income or expenditure during the financial year. The profit for the year was €0 (2024: €0).

Dividends

No dividends were paid or proposed during the year (2024: €0).

Directors

The director who served throughout the year was Gabriel Imboden.

Political Donations

The company made no political donations during the financial year (2024: €0).

Post Balance Sheet Events

There have been no significant events affecting the company since the year end.

Accounting Records

The directors believe that they have complied with the requirements of Sections 281 to 285 of the Companies Act 2014 with regard to the keeping of accounting records by employing persons with appropriate expertise and by providing adequate resources to the financial function. The accounting records of the company are maintained at the registered office at 3 Cavendish Row, Dublin 1, D01 A2T5.

On behalf of the Board



Gabriel Imboden
Director

Date: 12th February 2026

Nextlab Pharma Limited

Statement of directors' responsibilities on unaudited financial statements

General responsibilities

The directors are responsible for preparing the annual report and the statutory financial statements in accordance with applicable law and Generally Accepted Accounting Practice in Ireland, including the Accounting Standards issued by the Financial Reporting Council.

Company law requires the directors to prepare statutory financial statements for each financial year, which give a true and fair view of the assets, liabilities and financial position of the company, as at the end of the financial year, and profit or loss, for the financial year and otherwise comply with the Companies Act 2014. In preparing those financial statements, the directors are required to:

- Select suitable accounting policies and then apply them consistently;
- Make judgements and estimates that are reasonable and prudent;
- State whether the statutory financial statements have been prepared in accordance with applicable accounting standards, identify those standards and note the effect and the reasons for any material departure from those standards;
- Prepare the statutory financial statements on a going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy and enable them to ensure that the statutory financial statements and directors' report comply with the Companies Act 2014. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Directors' declaration on unaudited financial statements

In relation to the statutory financial statements as set out on pages 4 to 6:

The directors approve these statutory financial statements and confirm that they are responsible for them, including selecting the appropriate accounting policies, applying them consistently and making, on a reasonable and prudent basis, the judgements underlying them. They have been prepared on the going concern basis on the grounds that the company will continue in business.

The directors confirm that to the best of their knowledge and belief, the accounting records reflect all the transactions of the company for the accounting period.

On behalf of the Board



Gabriel Imboden
Director

Date: 12th February 2026

Nextlab Pharma Limited

Balance Sheet as at 30th June 2025

	2025 €	2024 €
Current Assets		
Cash at hand	1,000	1,000
	1,000	1,000
<hr/>		
Total Net Assets	1,000	1,000
<hr/>		
Capital & Reserves		
Called up share capital (Note 2)	1,000	1,000
Profit and loss account	0	0
	1,000	1,000
<hr/>		
Shareholders' Funds	1,000	1,000
<hr/>		

Statutory Statements

I/We, as director(s) of Nextlab Pharma Limited, state that:

(a) the company is availing itself of the audit exemption provided for by Chapter 16 of Part 6 of the Companies Act 2014;

(b) the company is availing itself of the exemption on the grounds that the conditions specified in Section 365(2) are satisfied;

(c) no notice has been received from any member or members of the company requiring the company to obtain an audit of its statutory financial statements for the financial year ended 30th June 2025;

(d) the company satisfies the criteria set out in Section 352 of the Companies Act 2014 (as a small company); and

(e) we acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and to prepare Financial Statements which give a true and fair

view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a year and to otherwise comply with the provisions of the Companies Act 2014 relating to Financial Statements so far as they are applicable to the company.

On behalf of the Board



Gabriel Imboden

Director

Date: 12th February 2026

Nextlab Pharma Limited

Notes to the financial statements for the year ended 30th June 2025

1. Accounting Policies

1.1. Accounting convention

The financial statements have been prepared on a going concern basis and in accordance with the historical cost convention. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 105 “The Financial Reporting Standard applicable to the Micro-Entities Regime” issued by the Financial Reporting Council.

1.2. Turnover

Turnover represents the total invoice value, excluding value-added tax, of sales during the period.

2. Share capital

	2025 €	2024 €
Authorised equity		
1,000 Ordinary Shares of €1 each	1,000	1,000
Allotted, called up and fully paid:		
1,000 Ordinary Shares of €1 each	1,000	1,000

3. Dormant Company Status

The company has not traded since incorporation and has been dormant throughout the current and preceding financial year. The company had no significant transactions during the year other than those required by law to maintain the company’s registration.

4. Post Balance Sheet Events

There have been no significant events affecting the company since the year end.

5. Approval of financial statements

The financial statements were approved by the board of directors on 12th February 2026.

— END OF FINANCIAL STATEMENTS —